Concepedia

Author

Prudence Ive

University of the WitwatersrandORCID

Also Known As

Dehlinger, Marjorie, Ingram, Charlotte, Liner, Jeff, P Ive, P. Ive, Prudence D Ive, Prudence D. Ive, Prudence Ive

64

Publications

3.6K

Citations

28

H-Index

33

Concepts

All Affiliations

University of the WitwatersrandJoint Clinical Research CentreBoston UniversityAmsterdam Institute for Global Health and DevelopmentUniversity of Amsterdam
PI

About

Prudence Ive is an author at University of the Witwatersrand specializing in medicine, hiv, and epidemiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

1.1K

2

Epidemiology

6

6

513

3

Public Health

5

5

437

4

Nursing

2

2

326

5

Social Sciences

1

1

76

Prudence Ive

×

42

Publications

3.5K

Citations

28

H-Index

YearCitations

Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis

Diane V. Havlir, Michelle A. Kendall, Prudence Ive,

New England Journal of Medicine

2011

538

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

David A. Cooper, Jayvant Heera, James Goodrich,

The Journal of Infectious Diseases

2010

265

Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial

Ian Sanne, Catherine Orrell, Matthew P. Fox,

The Lancet

2010

250

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt,

The Lancet

2015

248

SOLO

Joseph Gathe, Prudence Ive, Robin Wood,

AIDS

2004

196

Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study

Raph L Hamers, Rob Schuurman, Kim Sigaloff,

The Lancet Infectious Diseases

2011

194

Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa

Kim Sigaloff, Raph L Hamers, Carole L. Wallis,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2011

184

Patterns of HIV-1 Drug Resistance After First-Line Antiretroviral Therapy (ART) Failure in 6 Sub-Saharan African Countries: Implications for Second-Line ART Strategies

Raph L Hamers, Kim Sigaloff, Annemarie M. J. Wensing,

Clinical Infectious Diseases

2012

160

Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir

Alana T. Brennan, Denise Evans, Mhairi Maskew,

AIDS

2011

105

Prevention of HIV-1 Infection with Early Antiretroviral Therapy for the HPTN 052 Study Team*

Myron S. Cohen, Ying Qing Chen, Marybeth McCauley,

2011

86

Page 1